Sydney, May 29, 2007 (ACN Newswire) - Ventracor (ASX: VCR) (ADR: VTCRY) is about to commence two major clinical trials in the US after the company successfully completed a Feasibility Trial. The first is a Bridge to Transplant (BTT) Pivotal Trial for patients on the transplant list; the FDA recently approved the start of this trial. The trial will be conducted on approximately 140 patients in up to 40 centres. The second is the Destination Therapy Trial (DT) for patients who are not on the transplant list. The trial design is innovative and separated into two modules and the primary outcome is stroke-free survival (refer to full document link below).
